Microwave ablation of adenomyosis: five-year follow-up and risk factors for recurrence of symptoms

Zhang Y, Yi Zhang, Li M, Mengying Li, Jueying Li, Gao Q, Qian Gao, Jiu Yin, Yin J, Xiaoyu Zhao, Zhao X, Li J, Jingjing Li, Zhang Q, Qinghua Zhang, Liu J, Jianxin Liu, Shunshi Yang, Yang S
European journal of obstetrics, gynecology, and reproductive biology · 2026 · vol. 326 , pp. 115364 · doi:10.1016/j.ejogrb.2026.115364 · PMID:42580181 · W7202073865
Observational OA: hybrid CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-14 ⓘ

This retrospective study of 101 adenomyosis patients found that laparoscopic microwave ablation provides durable relief, with symptomatic recurrence independently predicted by larger preoperative uterine volume and elevated CA125 levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVES: To evaluate the long-term therapeutic efficacy of laparoscopy combined with transvaginal ultrasound-guided microwave ablation (MWA) for adenomyosis and to identify independent risk factors for postoperative symptomatic recurrence. MATERIAL AND METHODS: This single-centre retrospective cohort study enrolled 101 patients with adenomyosis who underwent laparoscopic transvaginal ultrasound-guided MWA at the Central Hospital of Wuhan, China, with a follow-up of up to 60 months. RESULTS: Kaplan-Meier analysis estimated cumulative symptomatic recurrence rates of 5.9%, 18.3%, 26.3%, 33.1%, 40.3%, and 43.2% at 6, 12, 24, 36, 48, and 60 months,respectively. Significant differences between the symptomatic recurrence (n = 35) and non-recurrence (n = 66) groups were observed in preoperative uterine volume, lesion type, ablation time, and postoperative adjuvant therapy use (all P < 0.05). Multivariable Cox regression (C-index = 0.809) identified three independent predictors of symptomatic recurrence: larger preoperative uterine volume (HR = 1.014; 95% CI 1.008-1.019; P < 0.001),elevated preoperative CA125 (HR = 1.003; 95% CI 1.000-1.006; P = 0.045),and postoperative adjuvant pharmacotherapy as a protective factor (HR = 0.255; 95% CI 0.077-0.842; P = 0.025). ROC analysis identified an optimal preoperative uterine volume cutoff of 268 mL (AUC = 0.814;specificity 97.0%) for stratifying symptomatic recurrence risk. CA125 showed limited standalone discriminative ability (AUC = 0.592). CONCLUSIONS: Laparoscopic combined with transvaginal ultrasound-guided microwave ablation is an effective and safe uterine-preserving treatment for AM. Preoperative uterine volume and postoperative adjuvant therapy are independent risk factors for symptomatic recurrence; CA125 levels are associated with symptomatic recurrence. While microwave ablation offers durable relief for uteri with a volume below 268 mL, those exceeding this threshold may require postoperative adjuvant therapy to optimize outcomes.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (18)

Source provenance

europepmc
last seen: 2026-10-13T06:10:10.580696+00:00
openalex
last seen: 2026-10-13T06:02:51.577429+00:00
pubmed
last seen: 2026-10-13T06:04:31.970809+00:00
License: CC0 · commercial use OK